John Lin

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

John Lin is an Assistant Professor at The University of Texas MD Anderson Cancer Center. His recent research focuses on the intersection of oncology and health economics, with particular attention to disparities in cancer treatment, cost reduction strategies for Medicare beneficiaries, and the application of machine learning in healthcare. He has contributed to various studies concerning the administration of systemic therapies and the quality of end-of-life care in older adults.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Matthew Campbell

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Alfred Garfall

Assistant Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES

View details

Paul A. Heidenreich

Stanford University

UNITED STATES

View details

William Chapin

University of Pennsylvania

UNITED STATES

View details

James Bentham

Senior Lecturer in Statistics

University of Kent

UNITED KINGDOM

View details

Yago Nieto

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ana Aparicio

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Nico Nortje

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

John Lin

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors

Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers

Reducing the Out-of-Pocket Costs of Disease-Modifying Therapies for Medicare Beneficiaries With Multiple Sclerosis

Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States

Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan

Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors

Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans

Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer

Achieving Value by Risk Stratification With Machine Learning Model or Clinical Risk Score in Acute Upper Gastrointestinal Bleeding: A Cost Minimization Analysis

Management of Prostate Cancer in Older Adults.

Bone Health in Prostate Cancer Survivors: Recent Lessons and Opportunities for Improvement.

Magnetic resonance imaging based superficial femoral artery velocity measurements in peripheral artery disease.

Guideline discordant care in patients with metastatic germ cell tumors

Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics.

Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan

Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab.

Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.

Evaluating the Role of Past Clinical Information on Risk Adjustment.

Multi-dimensional characterisation of global food supply from 1961-2013.

Collaborators (9)

Matthew Campbell

Jianjun Zhang

Alfred Garfall

Paul A. Heidenreich

William Chapin

James Bentham

Yago Nieto

Ana Aparicio

Nico Nortje

Make your next move.